原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义*

doi:10.3969/j.issn.1672-5069.2022.02.026

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (2): 255-258.doi: 10.3969/j.issn.1672-5069.2022.02.026

原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义^*

刘慧敏, 刘晓利, 王欣惠, 杨志云, 江宇泳

100015 北京市首都医科大学附属北京地坛医院中西医结合中心

收稿日期:2021-04-20 出版日期:2022-03-10 发布日期:2022-03-15
通讯作者: 江宇泳,E-mail:jyy11@126.com
作者简介:刘慧敏,女,38岁,博士研究生,副主任医师。主要从事中西医结合肝病的诊疗与研究。E-mail:lhm1205@126.com
基金资助:
*首都卫生发展科研专项基金资助( 编号:2016-4-2172);北京市医院管理局培育计划项目(编号:PZ2021030);北京中医药科技基金资助项目(编号:JJ2015-17)

Implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer

Liu Huimin, Liu Xiaoli, Wang Xinhui, et al

Integrated Centre of Traditional Chinese and Western Medicine, Ditan Hospital, Capital Medical University,Beijing,100015

Received:2021-04-20 Online:2022-03-10 Published:2022-03-15

摘要/Abstract

摘要： 目的了解原发性肝癌(PLC)患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化。方法 2018年6月～2019年12月我院诊治的PLC患者83例(巴塞罗那临床肝癌分期A期25例,B期23例,C期18例,D期17例)和健康人35例,采用流式细胞技术检测外周血CD4+T、CD8+T及Tc17(CD8+ IL-17)、Th17(CD4+ IL-17)和CD4+CD25+CD45RA+ Treg淋巴细胞百分比。结果 PLC患者外周血CD4+T淋巴细胞百分比为(32.8±8.5)%,显著低于健康人[(43.3±7.4)%,P ＜0.05],CD4+/CD8 +细胞比值为(0.9±0.3),显著低于健康人[(1.2±0.1),P ＜0.05]; PLC患者外周血Treg细胞[(6.4±0.9)%对(3.0±0.1)%]、Th17细胞[(5.0±1.1)%对(3.1±1.5)%]及Tc17细胞[(2.3±0.4)%对(1.0±0.2)%],均较健康人显著升高(P＜0.05);BCLC C/D期患者外周血CD4+CD25+CD45RA+ Treg细胞百分比较A/B期患者显著升高[(7.6±0.4) %对(5.3±0.5)%,P＜0.001], Th17(CD4+ IL-17)和Tc17(CD8+ IL-17)细胞百分比较A/B期亦显著升高[分别为(6.9±1.1)%对(5.4±0.6)%,P ＜0.01和(2.8±0.6)%对(1.6±0.4)%,P＜0.01]。结论 PLC患者外周血淋巴细胞亚群出现异常改变,可能与肿瘤的分期密切相关,为从免疫学角度开展调节T淋巴细胞失衡的免疫治疗提供了理论依据。

关键词: 原发性肝癌, CD4+T/CD8+T淋巴细胞, Tc17淋巴细胞, Th17/Treg细胞比值

Abstract: Objective The aim of this study was to investigate the implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer (PLC). Methods 83 patients with PLC (BCLC stage A in 25, stage B in 23, stage C in 18, and stage D in 17) and 35 healthy individuals were recruited in our hospital between June 2018 and December 2019, and the percentages of peripheral blood CD4+T, CD8+T, Tc17 (CD8+ IL-17), Th17(CD4+ IL-17) and CD4+CD25+CD45RA+ Treg lymphocytes were detected by flow cytometry. Results The percentage of peripheral blood CD4+ T lymphocytes in patients with PLC was (32.8±8.5)%, significantly lower than [(43.3±7.4)%, P ＜0.05], and the ratio of CD4+/CD8 + cells were (0.9±0.3), also significantly lower than [(1.2±0.1), P ＜0.05] in healthy control; the percentages of peripheral blood Treg cell[(6.4±0.9)% vs. (3.0±0.1)%], Th17 cell [(5.0±1.1)% vs. (3.1±1.5)%] and Tc17 cell [(2.3±0.4)% vs. (1.0±0.2)%] were all significantly increased as compared to those in the control (all P＜0.05); the percentage of CD4+CD25+CD45RA+ Treg cell in patients with BCLC stage C/D increased greatly compared to that in patients with stage A/B [(7.6±0.4) % vs.(5.3±0.5)%, P＜0.001], the percentages of Th17(CD4+ IL-17) cell and Tc17(CD8+ IL-17) cell also increased greatly compared to in patients with stage A/B[(6.9±1.1)% vs. (5.4±0.6)%, P ＜0.01 and (2.8±0.6)% vs. (1.6±0.4)%, P＜0.01]. Conclusion There is an immune imbalance of peripheral blood lymphocyte subsets in patients with PLC, which might hint the immunotherapy targeting at regulating T lymphocyte imbalance necessary in this setting.

Key words: Hepatoma, CD4+T/CD8+T lymphocytes, TC17 lymphocytes, Th17/Treg cell ratio

刘慧敏, 刘晓利, 王欣惠, 杨志云, 江宇泳. 原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义^*[J]. 实用肝脏病杂志, 2022, 25(2): 255-258.

Liu Huimin, Liu Xiaoli, Wang Xinhui, et al. Implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer[J]. Journal of Practical Hepatology, 2022, 25(2): 255-258.

参考文献

[1] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗规范(2019年版). 传染病信息, 2020,33(6):481-500.
[2] 李亚敏, 王瑞婷, 王瑛瑛. 冷循环射频消融术治疗原发性肝癌患者疗效及外周血Treg细胞的变化观察. 实用肝脏病杂志, 2021,24(1):123-126.
[3] 乔敏, 赵一鉴, 张建巧, 等. TACE联合射频消融治疗原发性肝癌患者疗效研究. 实用肝脏病杂志, 2021,24(1):119-122.
[4] 刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展. 实用肝脏病杂志, 2021,24(1):7-9.
[5] Avritscher R, Jo N, Polak U, et al. Hepatic arterial bland embolization increases Th17 cell Iifiltration in a syngeneic rat model of hepatocellular carcinoma. Cardiovasc Intervent Radiol, 2020,43(2):311-321.
[6] Hasan I, Gani R A, Lesmana L A, et al. The association between peripheral Th17, Th1, IL-17, and IFN-gamma levels and TACE response in patients with unresectable hepatocellular carcinoma with or without cirrhosis. Acta Med Indones, 2020,52(4):326-333.
[7] Peng Y, Yang J, Guo D, et al. Sufentanil postoperative analgesia reduce the increase of T helper 17 (Th17) cells and FoxP3(+) regulatory T (Treg) cells in rat hepatocellular carcinoma surgical model: A randomised animal study. BMC Anesthesiol, 2020,20(1):212.
[8] 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版). 中华消化外科杂志, 2017,16(7):635-647.
[9] Alejandro F, María E R, Carlos R D L, et al. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis, 2010,30(1):61-74.
[10] Ringelhan M, Pfister D, O'Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol, 2018,19(3):222-232.
[11] Jiang Y, Han Q J, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol, 2019,25(25):3151-3167.
[12] Huber M, Heink S, Grothe H, et al. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur J Immunol, 2009,39(7):1716-1725.
[13] Kuang D M, Peng C, Zhao Q, et al. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol, 2010,185(3):1544-1549.
[14] Ma S, Cheng Q, Cai Y, et al. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res, 2014,74(7):1969-1982.
[15] Mou H, Wu S, Zhao G, et al. Changes of Th17/Treg ratio in the transition of chronic hepatitis B to liver cirrhosis and correlations with liver function and inflammation. Exp Ther Med, 2019,17(4):2963-2968.
[16] Yao S X, Zhang G S, Cao H X, et al. Correlation between microRNA-21 and expression of Th17 and Treg cells in microenvironment of rats with hepatocellular carcinoma. Asian Pac J Trop Med, 2015,8(9):762-765.
[17] Li J, Lau G, Chen L, et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One, 2012,7(9):e46264.
[18] Cho H J, Kim S S, Nam J S, et al. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. Cytokine, 2017,95:118-125.
[19] Chen X, Du Y, Huang Z. CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. Immunol Lett, 2012,148(1):83-89.
[20] Takata Y, Nakamoto Y, Nakada A, et al. Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma. Cancer Lett, 2011,307(2):165-173.
[21] Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett, 2020,470:8-17.

原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义^*

Implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王婵, 沈长清, 吴晓琼, 邓程伟, 谢文蕊. 表柔比星药物洗脱微球肝动脉化疗栓塞术治疗不可手术切除的原发性肝癌患者临床疗效和安全性分析[J]. 实用肝脏病杂志, 2022, 25(2): 259-262.
[2]	周颜, 李国平, 邓俊, 杨美蓉, 吴晓霞, 张英, 朱宏英, 陈卫. 射频消融术治疗原发性肝癌患者接受胸腺素α₁维持治疗临床价值探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 907-910.
[3]	彭光明, 葛尚, 井桂银. 自适应性统计迭代重建联合低管电压提高肝细胞癌患者肝脏CT三期增强扫描图像质量研究[J]. 实用肝脏病杂志, 2021, 24(5): 737-740.
[4]	陈维, 魏涛, 杨岚, 伍小敏. 原发性肝癌患者癌组织NLRP3炎性小体表达状况研究[J]. 实用肝脏病杂志, 2021, 24(4): 544-547.
[5]	刘永昌, 赵殿堂, 孙启峰, 张启文. 吲哚菁绿荧光导航和三维可视化腹腔镜精准手术治疗原发性肝癌患者应用研究^*[J]. 实用肝脏病杂志, 2021, 24(4): 561-564.
[6]	王群先, 王云川, 陈有英. 肝脏部分切除术患者不同时机七氟烷吸入麻醉应用效果分析[J]. 实用肝脏病杂志, 2021, 24(4): 597-599.
[7]	安西全, 李燕, 孟根才次克. 替诺福韦联合索拉非尼治疗乙型肝炎相关中晚期原发性肝癌患者临床观察[J]. 实用肝脏病杂志, 2021, 24(4): 600-602.
[8]	谢宁, 黄娟秀, 严柳媚, 廖小莉. 长期核苷(酸)类抗病毒治疗的乙型肝炎肝硬化患者肝癌发生相关因素研究[J]. 实用肝脏病杂志, 2021, 24(3): 423-426.
[9]	莫娟, 闫文, 徐绍强. ALPPS治疗巨大原发性肝癌患者近远期疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 252-255.
[10]	赵闯, 梁超, 董宝剑, 陈祖涛. 原发性肝癌患者接受TACE术时行右美托咪定联合吗啡麻醉临床应用价值分析[J]. 实用肝脏病杂志, 2021, 24(2): 260-263.
[11]	朱雅萍, 魏金聚, 王妍心, 马俊琦. 异丙酚持续静脉泵入麻醉对接受微波消融治疗的原发性肝癌患者血管内皮糖萼和脑代谢的影响[J]. 实用肝脏病杂志, 2021, 24(2): 292-293.
[12]	李晓燕, 胡和平. 加强肝癌内科队伍建设,重视肝癌内科规范化和个性化诊疗决策[J]. 实用肝脏病杂志, 2021, 24(1): 1-3.
[13]	周新民, 丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用[J]. 实用肝脏病杂志, 2021, 24(1): 4-6.
[14]	张雪, 胥莹, 安文慧, 张帮婷, 杨雪芳. 五种评分系统判断TACE术治疗原发性肝癌患者发生肝功能不全效能比较研究[J]. 实用肝脏病杂志, 2021, 24(1): 111-114.
[15]	乔敏, 赵一鉴, 张建巧, 景赟杭. TACE联合射频消融治疗原发性肝癌患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 119-122.